Novavax to pursue the production of COVID-19 vaccine at the National Research Council
Today Prime Minister Justin Trudeau, today announced the government has signed a memorandum of understanding with Novavax to pursue the production of its COVID-19 vaccine at the National Research Council of Canada’s Biologics Manufacturing Centre in Montréal.
The Prime Minister also announced investments to support vaccine, therapeutic, and biomanufacturing projects in Canada. These include:
- Up to $25.1 million to Precision NanoSystems Incorporated (PNI), a Vancouver-based biotechnology company, to expand our ability to produce ribonucleic acid vaccines and future genetic medicines in Canada. PNI will build a $50.2 million biomanufacturing centre to produce vaccines and therapeutics for the prevention and treatment of diseases such as infectious diseases, rare diseases, cancer and other areas of unmet need.
- Up to $14 million to Edesa Biotech Inc. (Edesa), a biopharmaceutical company based in Markham, Ontario, to advance work on a monoclonal antibody therapy for acute respiratory distress syndrome, which is the leading cause of COVID-19 deaths. Edesa’s $18.7 million project has received Health Canada approval to conduct its phase 2 clinical trials, and has begun administering its treatment to clinical trial participants in Canada.
“Since the beginning of the pandemic, our top priority has been the health and safety of all Canadians. Today, we are investing in our biomanufacturing capacity so that we have the made-in-Canada vaccines and treatments we need to protect Canadians, now and in the future, and recover from the impacts of COVID-19.” The Rt. Hon. Justin Trudeau, Prime Minister of Canada
Canada has already approved vaccines to prevent COVID-19, which are being distributed across the country. The Pfizer-BioNTech COVID-19 vaccine was approved by Health Canada on December 9, 2020, and the Moderna COVID-19 vaccine was approved on December 23, 2020.
The memorandum of understanding with Novavax enables the government to pursue options to produce the Novavax COVID-19 vaccine at the National Research Council’s Biologics Manufacturing Centre in Montréal, once both the vaccine candidate and the facility receive Health Canada approvals. Novavax recently initiated the rolling submission process for regulatory approval to Health Canada.